Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2011-02-01Clinical Trial Update: Depression Care Management for Depressed Elders in China Primary Care [Phase 4]
This ClinicalTrials.gov study is a Phase 4 trial evaluating depression care management for depressed elders in primary care settings in Chin…
-
FDA approval · 2011-01-31FDA Approved: PRISTIQ EXTENDED-RELEASE — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
The FDA approved a supplemental application for Pristiq Extended-Release (desvenlafaxine succinate) from Wyeth Pharmaceuticals (a Pfizer sub…
-
FDA approval · 2011-01-30FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for Paroxetine hydrochloride by Zydus Lifesciences Limited, indicating an update to the labeling or …
-
CLINICAL_TRIALS trial_result · 2011-01-26Clinical Trial Update: Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder [Phase 3]
Phase 3 study evaluating the efficacy of Seroquel SR in combination with an antidepressant for treatment of Major Depressive Disorder.
-
CLINICAL_TRIALS research · 2011-01-26Clinical Trial Update: Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder
This completed retrospective study evaluates how Desvenlafaxine Succinate Sustained-Release (Pristiq) is utilized by psychiatrists and prima…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2011-01-25Clinical Trial Update: Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy Subjects [Phase 1]
This document reports the completion of a Phase 1 safety, pharmacokinetics, and pharmacodynamics study of BMS-866949 in healthy subjects.
-
CLINICAL_TRIALS trial_result · 2011-01-25Clinical Trial Update: Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression [Phase 1, Phase 2]
A Phase 1/2 clinical trial comparing risperidone versus olanzapine as add-on therapy in treatment-resistant major depressive disorder has co…
-
CLINICAL_TRIALS trial_result · 2011-01-25Clinical Trial Update: Single Dose Study of BMS-820836 [Phase 1]
The document reports the completion of a single-dose Phase 1 study of the investigational antidepressant BMS-820836.
-
CLINICAL_TRIALS trial_result · 2011-01-25Clinical Trial Update: Treatments for Psychogenic Nonepileptic Seizures (NES) [Phase 4]
Phase 4 trial update on treatments for psychogenic nonepileptic seizures (NES) in conversion disorder, with comorbid depression and PTSD; re…
-
FDA approval · 2011-01-21FDA Approved: VIIBRYD — Original Application (Allergan, Inc.)
FDA approved VIIBRYD (vilazodone hydrochloride) from Allergan for the treatment of adults with major depressive disorder (original applicati…
-
FDA approval · 2011-01-21FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for bupropion hydrochloride from BluePoint Laboratories, approving changes to an existing generic pr…
-
CLINICAL_TRIALS trial_result · 2011-01-21Clinical Trial Update: AZD6765 for Treatment Resistant Depression [Phase 2]
Phase 2 trial of AZD6765 for treatment-resistant depression has completed.
-
FDA approval · 2011-01-20FDA Approved: CITALOPRAM — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for citalopram from Torrent Pharmaceuticals Limited.
-
CLINICAL_TRIALS research · 2011-01-20Clinical Trial Update: Effects of Maternal Depressive Symptomatology on Pregnancy Outcomes and Newborn Development --- How is Paternal Psychopathology Involved?
A clinical trial update examining how maternal depressive symptoms influence pregnancy outcomes and newborn development. The study also cons…
-
CLINICAL_TRIALS trial_result · 2011-01-19Clinical Trial Update: Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism [Phase 4]
A Phase 4 clinical trial from the University of Ottawa examined treatment-resistant depression, hippocampal atrophy, and serotonin genetic p…
-
FDA approval · 2011-01-13FDA Approved: CITALOPRAM — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for Citalopram submitted by Amneal Pharmaceuticals LLC.
-
FDA approval · 2011-01-13FDA Approved: NEFAZODONE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for nefazodone hydrochloride (Teva Pharmaceuticals) to modify the approved generic product, per the …
-
CLINICAL_TRIALS trial_result · 2011-01-12Clinical Trial Update: The Efficacy of Omega-3 Fatty Acids in Maintaining Optimal Mental Health in Elderly People [NA]
A completed clinical trial evaluated whether omega-3 fatty acids help maintain mental health in elderly people with cognitive impairment or …
-
CLINICAL_TRIALS trial_result · 2011-01-07Clinical Trial Update: Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl [Phase 4]
This Phase 4 trial assesses the proportion of depressed outpatients who are poor metabolizers of extended-release venlafaxine hydrochloride.
-
CLINICAL_TRIALS trial_result · 2011-01-05Clinical Trial Update: Safety and Antidepressant Effects of Rellidep in Major Depressive Disorder [Phase 2, Phase 3]
This clinical trial update reports safety data and antidepressant effects of the investigational drug Rellidep in adults with major depressi…
-
FDA label_change · 2010-12-30FDA Approved: NORTRIPTYLINE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Nortriptyline hydrochloride from Teva Pharmaceuticals USA, Inc., typically indicating a labeling…
-
FDA approval · 2010-12-29FDA Approved: PRISTIQ EXTENDED-RELEASE — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
The FDA approved a supplemental application for Pristiq Extended-Release (desvenlafaxine succinate), indicating an authorized update related…
-
CLINICAL_TRIALS trial_result · 2010-12-29Clinical Trial Update: DBS in Treatment Resistant Major Depression [Phase 3]
Phase 3 clinical trial update for deep brain stimulation in treatment-resistant major depressive disorder. The current status is unknown.
-
CLINICAL_TRIALS research · 2010-12-28Clinical Trial Update: Tailored Internet-delivered Cognitive Behaviour Therapy for Symptoms of Depression and Comorbid Problems [NA]
A completed clinical trial evaluating tailored internet-delivered cognitive behavioural therapy for symptoms of depression with comorbid anx…
-
FDA approval · 2010-12-14FDA Approved: VENLAFAXINE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals' generic venlafaxine via an Original Application (ANDA). It is indicated for major depressive disorder,…